NKX2-5在系统性硬化症血管重构中失调激活的分子基础
本研究探讨系统性硬化症相关肺动脉高压血管中NKX2-5表达激活的机制及遗传变异。发现NKX2-5在重构血管和平滑肌细胞中表达增加,rs3131917与硬皮病相关(P=0.029),疾病相关SNP位于新增强子中通过GATA-6、c-Jun、MEF2C及TEAD1/YAP1复合物调控NKX2-5转录。
要点
- NKX2-5在SSc相关PH患者活检的重构血管和平滑肌细胞中表达增加
- rs3131917与硬皮病相关(P=0.029,2个独立队列Meta分析)
- 疾病相关SNP位于新增强子,通过GATA-6、c-Jun、MEF2C及TEAD1/YAP1调控NKX2-5转录
核心结论
- NKX2-5与硬皮病、肺动脉高压和纤维化存在遗传关联。
- 功能证据揭示上游启动子与下游新增强子相互作用导致PASMCs中NKX2-5转录激活的调控机制。
- 该机制可作为以血管重构为特征的心血管疾病中NKX2-5激活的模型。
研究设计与样本
- 研究类型为分子机制研究,包括患者活检样本和肺动脉平滑肌细胞(PASMCs)分析。
- 对NKX2-5位点的疾病相关推定功能性单核苷酸多态性(SNPs)进行克隆并在报告基因实验中研究。
- 通过蛋白-DNA结合实验、染色质免疫沉淀实验和RNA沉默分析进一步检查SNP功能。
- 对2个独立硬皮病队列进行Meta分析。
主要发现
- SSc相关PH患者活检样本中NKX2-5表达增加,定位于重构血管和PASMCs。
- 2个独立硬皮病队列Meta分析显示rs3131917与硬皮病相关(P=0.029)。
- 疾病相关SNPs位于新功能性增强子中,通过GATA-6、c-Jun和肌细胞特异性增强因子2C的结合增加NKX2-5转录活性。
- 表征了激活因子/共激活因子转录增强因子结构域1(TEAD1)/Yes相关蛋白1(YAP1)复合物,其结合于rs3095870,TEAD1结合风险等位基因并激活NKX2-5转录。
关键数值与推荐
- rs3131917与硬皮病相关(P=0.029,2个独立队列Meta分析)。
- 疾病相关SNPs位于新功能性增强子中,通过GATA-6、c-Jun和肌细胞特异性增强因子2C结合增加NKX2-5转录活性。
- TEAD1/YAP1复合物结合于rs3095870,TEAD1结合风险等位基因并激活NKX2-5转录。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: NKX2-5 is a homeobox transcription factor that is required for the formation of the heart and vessels during development, with significant postnatal down-regulation and reactivation in disease states, characterized by vascular remodeling. The purpose of this study was to investigate mechanisms that activate NKX2-5 expression in diseased vessels, such as systemic sclerosis (scleroderma; SSc)-associated pulmonary hypertension (PH), and to identify genetic variability that potentially underlies susceptibility to specific vascular complications. METHODS: We explored NKX2-5 expression in biopsy samples from patients with SSc-associated PH and in pulmonary artery smooth muscle cells (PASMCs) from patients with scleroderma. Disease-associated putative functional single-nucleotide polymorphisms (SNPs) at the NKX2-5 locus were cloned and studied in reporter gene assays. SNP function was further examined through protein-DNA binding assays, chromatin immunoprecipitation assays, and RNA silencing analyses. RESULTS: Increased NKX2-5 expression in biopsy samples from patients with SSc-associated PH was localized to remodeled vessels and PASMCs. Meta-analysis of 2 independent scleroderma cohorts revealed an association of rs3131917 with scleroderma (P = 0.029). We demonstrated that disease-associated SNPs are located in a novel functional enhancer, which increases NKX2-5 transcriptional activity through the binding of GATA-6, c-Jun, and myocyte-specific enhancer factor 2C. We also characterized an activator/coactivator transcription-enhancer factor domain 1 (TEAD1)/Yes-associated protein 1 (YAP1) complex, which was bound at rs3095870, another functional SNP, with TEAD1 binding the risk allele and activating the transcription of NKX2-5. CONCLUSION: NKX2-5 is genetically associated with scleroderma, pulmonary hypertension, and fibrosis. Functional evidence revealed a regulatory mechanism that results in NKX2-5 transcriptional activation in PASMCs through the interaction of an upstream promoter and a novel downstream enhancer. This mechanism can act as a model for NKX2-5 activation in cardiovascular disease characterized by vascular remodeling.
引用
- Dritsoula A, Papaioannou I, Guerra SG, et al. Molecular Basis for Dysregulated Activation of NKX2-5 in the Vascular Remodeling of Systemic Sclerosis. Arthritis Rheumatol. 2018. PMID: 29342503. doi:10.1002/art.40419
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。